{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:30:09Z","timestamp":1791009009205,"version":"4.1.0"},"reference-count":173,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Chronic lymphocytic leukemia is a lymphoproliferative disorder marked by the expansion of monoclonal, mature CD5+CD23+ B cells in peripheral blood, secondary lymphoid tissues, and bone marrow. The disease exhibits significant heterogeneity, with numerous somatic genetic alterations identified in the neoplastic clone, notably mutated TP53 and immunoglobulin heavy chain mutational statuses. Recent studies emphasize the pivotal roles of genetics and patient fragility in treatment decisions. This complexity underscores the need for a personalized approach, tailoring interventions to individual genetic profiles for heightened efficacy. The era of personalized treatment in CLL signifies a transformative shift, holding the potential for improved outcomes in the conquest of this intricate hematologic disorder. This review plays a role in elucidating the evolving CLL treatment landscape, encompassing all reported genetic factors. Through a comprehensive historical analysis, it provides insights into the evolution of CLL management. Beyond its retrospective nature, this review could be a valuable resource for clinicians, researchers, and stakeholders, offering a window into the latest advancements. In essence, it serves as a dynamic exploration of our current position and the promising prospects on the horizon.<\/jats:p>","DOI":"10.3390\/pharmaceutics16010055","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T06:18:13Z","timestamp":1703830693000},"page":"55","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9517-0351","authenticated-orcid":false,"given":"Mar\u00eda Del Mar","family":"S\u00e1nchez Su\u00e1rez","sequence":"first","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1185-694X","authenticated-orcid":false,"given":"Alicia","family":"Mart\u00edn Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-1050","authenticated-orcid":false,"given":"Carolina","family":"Alarc\u00f3n-Payer","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Rodr\u00edguez-Gil","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica Hematolog\u00eda y Hemoterapia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Eduardo","family":"Poquet-Jornet","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital de D\u00e9nia Marina Salud, 03700 D\u00e9nia, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4081-3050","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Puerta Puerta","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica Hematolog\u00eda y Hemoterapia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Jim\u00e9nez Morales","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, 18014 Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-022-00756-9","article-title":"Chronic lymphocytic leukemia treatment algorithm 2022","volume":"12","author":"Hampel","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_2","unstructured":"Mukkamalla, S.K.R., Taneja, A., Malipeddi, D., and Master, S.R. (2023, July 15). Chronic Lymphocytic Leukemia, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/29261864\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2012-05-431452","article-title":"Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor","volume":"121","author":"Reinart","year":"2013","journal-title":"Blood"},{"key":"ref_4","unstructured":"The Surveillance E, and End Results (SEER) Program of the National Cancer Institute (2023, July 15). Cancer Stat Facts: Leukemia\u2014Chronic LymphocyticLeukemia (CLL), Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100930","DOI":"10.1016\/j.blre.2022.100930","article-title":"CLL update 2022: A continuing evolution in care","volume":"54","author":"Kay","year":"2022","journal-title":"Blood Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"a035220","DOI":"10.1101\/cshperspect.a035220","article-title":"Chronic Lymphocytic Leukemia","volume":"11","author":"Chiorazzi","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1084\/jem.20120833","article-title":"Cellular origin and pathophysiology of chronic lymphocytic leukemia","volume":"209","author":"Seifert","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.18465","article-title":"Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications","volume":"200","author":"Kulis","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/leu.2010.208","article-title":"TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations","volume":"24","author":"Zenz","year":"2010","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1038\/sj.onc.1207532","article-title":"DNA damage-induced apoptosis","volume":"23","author":"Norbury","year":"2004","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s00277-018-3503-6","article-title":"Prognostic and therapeutic stratification in CLL: Focus on 17p deletion and p53 mutation","volume":"97","author":"Buccheri","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_20","first-page":"D777","article-title":"COSMIC: The catalogue of somatic mutations in cancer","volume":"45","author":"Tate","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"826245","DOI":"10.3389\/fonc.2021.826245","article-title":"\u201cDouble-Hit\u201d Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes","volume":"11","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Maher, N., Mouhssine, S., Matti, B.F., Alwan, A.F., and Gaidano, G. (2023). Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210374"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","article-title":"Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: A study by ERIC in HARMONY","volume":"37","author":"Mansouri","year":"2023","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Al Jamal, I., Parquet, M., Guiyedi, K., Aoufouchi, S., Le Guillou, M., Rizzo, D., Pollet, J., Dupont, M., Boulin, M., and Faumont, N. (Haematologica, 2023). IgH 3\u2032RR recombination uncovers a non-germinal center imprint and c-MYC-dependent IgH rearrangement in unmutated chronic lymphocytic leukemia, Haematologica, advance online publication.","DOI":"10.3324\/haematol.2023.282897"},{"key":"ref_25","unstructured":"Medina, A., Ram\u00edrez, A., H\u00e9rnandez, J.A., Loscertales, J., Serna, J., Andreu, R., Y\u00e1\u00f1ez, L., Terol, M.J., Gonz\u00e1lez, M., and Delgado, J. (2023, July 25). Guia Nacional de Leucemia Linf\u00e1tica Cr\u00f3nica y Linfoma Linfoc\u00edtico. Available online: https:\/\/www.sehh.es\/images\/stories\/recursos\/2020\/05\/18\/Guia-Clinica-LLC-abril-2020.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.4161\/cc.22223","article-title":"cIAP2 represses IKK\u03b1\/\u03b2-mediated activation of MDM2 to prevent p53 degradation","volume":"11","author":"Lau","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1757","DOI":"10.1002\/cnr2.1757","article-title":"Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients","volume":"6","author":"Sadria","year":"2023","journal-title":"Cancer Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fonc.2018.00229","article-title":"NOTCH1 Aberrations in Chronic Lymphocytic Leukemia","volume":"8","author":"Rosati","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bjh.18458","article-title":"ATM serine\/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours","volume":"199","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/leu.2017.201","article-title":"Rare germline variants in ATM are associated with chronic lymphocytic leukemia","volume":"31","author":"Tiao","year":"2017","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","article-title":"Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome","volume":"123","author":"Pinyol","year":"2014","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood-2015-05-648634","article-title":"Prognostic relevance of MYD88 mutations in CLL: The jury is still out","volume":"126","author":"Baliakas","year":"2015","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: From genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mhibik, M., Wiestner, A., and Sun, C. (2019). Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010068"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/10245332.2015.1101965","article-title":"Increased regulatory T cells in acute lymphoblastic leukaemia patients","volume":"21","author":"Idris","year":"2016","journal-title":"Hematology"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Andreescu, M., Berbec, N., and Tanase, A.D. (2023). Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072731"},{"key":"ref_41","first-page":"83","article-title":"Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells","volume":"58","author":"Huang","year":"1993","journal-title":"Int. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/leu.2011.12","article-title":"IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells","volume":"25","author":"Coscia","year":"2011","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13994","DOI":"10.1002\/jcp.28086","article-title":"Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Arruga, F., Gyau, B.B., Iannello, A., Vitale, N., Vaisitti, T., and Deaglio, S. (2020). Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051825"},{"key":"ref_45","first-page":"4384","article-title":"Classification of lymphoid neoplasms: The microscope as a tool for disease discovery","volume":"112","author":"Jaffe","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4049\/jimmunol.1800241","article-title":"Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity","volume":"200","author":"Alhakeem","year":"2018","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s13277-012-0628-4","article-title":"Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia","volume":"34","author":"Ghalamfarsa","year":"2013","journal-title":"Tumour Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V76.2.393.bloodjournal762393","article-title":"Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease","volume":"76","author":"Foa","year":"1990","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.bbmt.2017.04.023","article-title":"IFN-\u03b1 is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: Results of a registry study","volume":"23","author":"Mo","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","article-title":"Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia","volume":"99","author":"Tsukada","year":"2002","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2016000984","article-title":"Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment","volume":"1","author":"Serra","year":"2016","journal-title":"Blood Adv."},{"key":"ref_53","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, WHO Press."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer InstituteWorking Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ajcp\/108.4.378","article-title":"Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b)","volume":"108","author":"Moreau","year":"1997","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rosenquist","year":"2018","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/ijlh.13567","article-title":"Concordance between flow cytometry CLL scores","volume":"43","author":"Sorigue","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"European Research Initiative on CLL. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Ghia","year":"2007","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"International CLL IPI Working Group (2016). An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol., 17, 779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/leu.2013.333","article-title":"On the way towards a \u2018CLL prognostic index\u2019: Focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort","volume":"28","author":"Cortese","year":"2014","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.24004","article-title":"Validation of a new prognostic index for patients with chronic lymphocytic leukemia","volume":"115","author":"Shanafelt","year":"2009","journal-title":"Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gao, R., Du, K., Liang, J., Xia, Y., Wu, J., Li, Y., Pan, B., Wang, L., Li, J., and Xu, W. (2023). Low Serum Cholesterol Level Is a Significant Prognostic Factor That Improves CLL-IPI in Chronic Lymphocytic Leukaemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087396"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00277-007-0375-6","article-title":"Cholesterol levels in patients with multiple myeloma","volume":"87","author":"Yavasoglu","year":"2008","journal-title":"Ann. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1158\/0008-5472.CAN-07-0212","article-title":"Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma","volume":"67","author":"Lim","year":"2007","journal-title":"Cancer Res."},{"key":"ref_71","first-page":"23","article-title":"Cholesterol Levels in Patients with Chronic Lymphocytic Leukemia","volume":"109","author":"Yavasoglu","year":"2017","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_72","first-page":"41","article-title":"The Treatment of Chronic Lymphatic Leukemia","volume":"116","author":"Tresckow","year":"2019","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2015.136051","article-title":"Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia","volume":"101","author":"Rasi","year":"2016","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.16051","article-title":"Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia","volume":"187","author":"Huang","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11899-019-00511-1","article-title":"Relevance of Prognostic Fac- tors in the Era of Targeted Therapies in CLL","volume":"14","author":"Kittai","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Tadmor, T., and Levy, I. (2021). Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents. Cancers, 13.","DOI":"10.3390\/cancers13205141"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102619","DOI":"10.1016\/j.ctrv.2023.102619","article-title":"From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia","volume":"120","author":"Abrisqueta","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"101538","DOI":"10.1016\/j.jgo.2023.101538","article-title":"Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia","volume":"14","author":"Johnson","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jgo.2013.04.008","article-title":"Does the Multidimensional Prognostic Index (MPI), based on a Comprehensive Geriatric Assessment (CGA), \u00bfpredict mortality in cancer patients? Results of a prospective observational trial","volume":"4","author":"Giantin","year":"2013","journal-title":"J. Geriatr. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/10428194.2018.1508674","article-title":"A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients","volume":"60","author":"Molica","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbmt.2019.08.022","article-title":"Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients","volume":"26","author":"Huang","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Arguello-Tomas, M., Albiol, N., and Moreno, C. (2023). Frontline therapy in Chronic Lymphocytic Leukemia. Acta Haematol.","DOI":"10.1159\/000534730"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: A systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"CLL Trialists Collaborative Group (1999). Chemotherapeutic options in chronic lymphocytic leukemia. J. Natl. Cancer Inst., 91, 861\u2013868.","DOI":"10.1093\/jnci\/91.10.861"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia","volume":"29","author":"Gribben","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"CLL Trialists\u2019 Collaborative Group (2012). Systematic review of purine analog treatment for chronic lymphocytic leukemia: Lessons for future trials. Haematologica, 97, 428\u2013436.","DOI":"10.3324\/haematol.2011.053512"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00277-012-1660-6","article-title":"Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia","volume":"92","author":"Niederle","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_95","first-page":"CD008079","article-title":"Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia","volume":"11","author":"Bauer","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2014-07-586610","article-title":"Obinutuzumab (GA101) in relapsed\/refractory chronic lymphocytic leukemia: Final data from the phase 1\/2 GAUGUIN study","volume":"124","author":"Cartron","year":"2014","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): Interim analysis of a multicentre, open label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/HS9.0000000000000336","article-title":"Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated with FCR Versus BR (CLL10 Trial of the GCLLSG)","volume":"4","author":"Kutsch","year":"2020","journal-title":"Hemasphere"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1182\/bloodadvances.2022009594","article-title":"Bruno A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial","volume":"7","author":"Michallet","year":"2023","journal-title":"Blood Adv."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"TPS7582","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7582","article-title":"The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL)","volume":"36","author":"Niemann","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjh.14464","article-title":"Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia","volume":"176","author":"Robak","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_109","unstructured":"FDA (2023, September 30). Copiktra (Duvelisib): Drug Safety Communication\u2014FDA Warns about Possible Increased Risk of Death and Serious Side Effects, Available online: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/copiktra-duvelisib-drug-safety-communication-fda-warns-about-possible-increased-risk-death-and."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4, \u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: A multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-134783","article-title":"Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+Chl) in patients with treatment Na\u00efve (TN) and relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): Results from the phase 3 Unity-CLL study","volume":"136","author":"Gribben","year":"2020","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.15080","article-title":"Optimising outcomes for patients with chronic lympho- cytic leukaemia on ibrutinib therapy: European recommendations for clinical practice","volume":"180","author":"Gribben","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib Treatment for First-Line and Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib\/II PCYC-1102 Study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-021-01342-x","article-title":"Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202","volume":"35","author":"Ruppert","year":"2021","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"Furman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment\u2014From chemoimmunotherapy to targeted and individualized therapy","volume":"15","author":"Burger","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/onco.13685","article-title":"EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia","volume":"26","author":"Delgado","year":"2021","journal-title":"Oncologist"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib Versus Investigator\u2019s Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximabor Bendamustine Plus Rituximab in Relapsedor Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2217\/fon-2022-0456","article-title":"MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"18","author":"Ryan","year":"2022","journal-title":"Future Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood-2021-148457","article-title":"SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"138","author":"Tam","year":"2021","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/fon-2019-0844","article-title":"ALPINE: Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"16","author":"Hillmen","year":"2020","journal-title":"Future Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: Phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed Duration of Venetoclax-Rituximab in Relapsed\/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","volume":"37","author":"Kater","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: Obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Acebes-Huerta, A., Huergo-Zapico, L., Gonzalez-Rodriguez, A.P., Fernandez-Guizan, A., Payer, A.R., L\u00f3pez-Soto, A., and Gonzalez, S. (2014). Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/265840"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study","volume":"24","author":"Miller","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces com- plete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2352-3026(17)30168-0","article-title":"Lenalidomide mainte- nance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Zaritskey","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000534341","article-title":"Cellular therapy in chronic lymphocytic leukemia: Have we advanced in the last decade?","volume":"146","author":"Katz","year":"2023","journal-title":"Acta Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","article-title":"Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines committee of the American society for blood and marrow transplantation","volume":"22","author":"Kumar","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2016.282","article-title":"Long-term survival of patients with CLL after allogeneic transplantation: A report from the European society for blood and marrow transplantation","volume":"52","author":"Niederwieser","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s00432-019-03014-x","article-title":"Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning","volume":"145","author":"Andersen","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3109\/10428194.2014.930848","article-title":"Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: Consult-transplant versus consult- no-transplant analysis","volume":"56","author":"Poon","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: Phase 1 cohort of lisocabtagene maraleucel (lisocel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"ref_151","unstructured":"Grupo Espa\u00f1ol de Leucemia Linfoc\u00edtica Cr\u00f3nica (GELLLC) (2023, September 28). Gu\u00edas de Tratamiento LLC. Available online: https:\/\/www.gellc.es\/images\/pdf\/GUIA_GELLC_04_2023.pdf."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"107016","DOI":"10.1016\/j.leukres.2023.107016","article-title":"Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update","volume":"125","author":"Owen","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s10238-023-01007-2","article-title":"Expert consensus on the management of chronic lymphocytic leukaemia in Asia","volume":"23","author":"Tse","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"ref_155","unstructured":"Wendtner, C.M., Al-Sawaf, O., Binder, M., Dreger, P., Eichhorst, B., Gregor, M., Greil, R., Hallek, M., Holtkamp, U., and Knauf, W.U. (2023, September 28). Chronische Lymphatische Leuk\u00e4mie. Available online: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/chronische-lymphatische-leukaemie-cll\/@@guideline\/html\/index.html#ID0ECWAE."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN Guidelines\u00ae Insights: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 3.2022","volume":"20","author":"Wierda","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11864-023-01112-0","article-title":"Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: A Review","volume":"24","author":"Islam","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11899-023-00700-z","article-title":"Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL)","volume":"18","author":"Odetola","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL-2 with Venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/s11864-023-01129-5","article-title":"Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia","volume":"24","author":"Taghiloo","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","article-title":"Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: A new treatment strategy for ibrutinib-resistant CLL","volume":"132","author":"Reiff","year":"2018","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e2019024","DOI":"10.4084\/mjhid.2019.024","article-title":"Relapsed\/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?","volume":"11","author":"Cuneo","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2023.03.010","article-title":"Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results from a Multi-Center International Study","volume":"23","author":"Shadman","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and Obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: A single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"E879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, Obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Karr, M., and Roeker, L. (2023). A History of Targeted Therapy Development and Progress in Novel-Novel Combinations for Chronic Lymphocytic Leukemia (CLL). Cancers, 15.","DOI":"10.3390\/cancers15041018"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/1\/55\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:44:07Z","timestamp":1760132647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/1\/55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":173,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["pharmaceutics16010055"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16010055","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}